PH12020500601A1 - Contraceptive composition with reduced cardiovascular effects - Google Patents

Contraceptive composition with reduced cardiovascular effects

Info

Publication number
PH12020500601A1
PH12020500601A1 PH12020500601A PH12020500601A PH12020500601A1 PH 12020500601 A1 PH12020500601 A1 PH 12020500601A1 PH 12020500601 A PH12020500601 A PH 12020500601A PH 12020500601 A PH12020500601 A PH 12020500601A PH 12020500601 A1 PH12020500601 A1 PH 12020500601A1
Authority
PH
Philippines
Prior art keywords
reduced
thromboembolism
risk
cardiovascular effects
reduced cardiovascular
Prior art date
Application number
PH12020500601A
Other languages
English (en)
Inventor
Maud Jost
Glwadys Rausin
Original Assignee
Estetra Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra Sprl filed Critical Estetra Sprl
Publication of PH12020500601A1 publication Critical patent/PH12020500601A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PH12020500601A 2018-02-07 2020-07-13 Contraceptive composition with reduced cardiovascular effects PH12020500601A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18155571 2018-02-07
EP18160586 2018-03-07
PCT/EP2019/052980 WO2019154899A1 (en) 2018-02-07 2019-02-07 Contraceptive composition with reduced cardiovascular effects

Publications (1)

Publication Number Publication Date
PH12020500601A1 true PH12020500601A1 (en) 2021-05-17

Family

ID=65278388

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020500601A PH12020500601A1 (en) 2018-02-07 2020-07-13 Contraceptive composition with reduced cardiovascular effects

Country Status (20)

Country Link
EP (2) EP4140489A1 (https=)
JP (2) JP2021513507A (https=)
KR (1) KR102717921B1 (https=)
CN (2) CN115429806A (https=)
AU (1) AU2019219070B2 (https=)
CA (2) CA3178181A1 (https=)
CL (1) CL2020002017A1 (https=)
EC (1) ECSP20054822A (https=)
GE (2) GEAP202215414A (https=)
IL (1) IL276584B2 (https=)
JO (1) JOP20200169A1 (https=)
MA (1) MA51733A (https=)
NZ (1) NZ766027A (https=)
PH (1) PH12020500601A1 (https=)
PY (1) PY1908892A (https=)
SG (1) SG11202007163WA (https=)
TW (1) TWI845496B (https=)
UA (1) UA126746C2 (https=)
UY (1) UY38075A (https=)
WO (1) WO2019154899A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN111989105B (zh) 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TWI893101B (zh) * 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
WO2022248733A1 (en) 2021-05-28 2022-12-01 Neuralis Sa Use of estetrol in treatment of respiratory infection diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
EP1390042B1 (en) * 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
CA2762640A1 (en) * 2009-05-22 2010-11-25 Stefanie Lindemann Medication for oral administration, comprising at least one estrogen and/or at least one gestagen and at least one probiotic bacterial strain
WO2012055840A1 (en) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
JP6447931B2 (ja) * 2013-12-12 2019-01-09 ドネスタ バイオサイエンス ビー.ブイ.Donesta Bioscience B.V. エステトロール成分を含有する口腔内崩壊固体単位剤形
CA3041016C (en) 2016-10-28 2023-09-05 Estetra Sprl Method for the management of dysmenorrhea and menstrual pain
KR102712911B1 (ko) * 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법

Also Published As

Publication number Publication date
JP2024009834A (ja) 2024-01-23
CN111683664A (zh) 2020-09-18
JOP20200169A1 (ar) 2020-07-07
IL276584B2 (en) 2024-10-01
CA3178181A1 (en) 2019-08-15
IL276584B1 (en) 2024-06-01
EP3749327A1 (en) 2020-12-16
AU2019219070B2 (en) 2024-12-19
TW202011967A (zh) 2020-04-01
SG11202007163WA (en) 2020-08-28
GEAP202215414A (en) 2022-04-25
ECSP20054822A (es) 2020-12-31
AU2019219070A1 (en) 2020-09-24
IL276584A (en) 2020-09-30
JP7651645B2 (ja) 2025-03-26
NZ766027A (en) 2026-03-27
GEP20227407B (en) 2022-08-25
CN115429806A (zh) 2022-12-06
WO2019154899A1 (en) 2019-08-15
KR20200118464A (ko) 2020-10-15
CA3089804A1 (en) 2019-08-15
UY38075A (es) 2019-10-01
MA51733A (fr) 2020-12-16
CL2020002017A1 (es) 2020-12-04
EP4140489A1 (en) 2023-03-01
PY1908892A (es) 2019-10-15
TWI845496B (zh) 2024-06-21
JP2021513507A (ja) 2021-05-27
UA126746C2 (uk) 2023-01-18
KR102717921B1 (ko) 2024-10-16

Similar Documents

Publication Publication Date Title
PH12020500601A1 (en) Contraceptive composition with reduced cardiovascular effects
de Araujo Peixoto et al. Tectonic evolution of the Juvenile Tonian Serra da Prata magmatic arc in the Ribeira belt, SE Brazil: Implications for early west Gondwana amalgamation
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
GEP20227396B (en) Compounds and their uses for alleviating menopause-associated symptoms
GEP20227395B (en) Compounds and their uses for alleviating menopause-associated symptoms
EP4327866A3 (en) Mirikizumab in the treatment of ulcerative colitis
EP3396532A3 (en) Dynamic precision for neural network compute operations
MX2021007709A (es) Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular.
MX2025002836A (es) Metodos para administrar corticosteroides
MY177369A (en) Reducing proinflammatory response
TN2017000499A1 (en) Orodispersible dosage unit containing an estetrol component
PH12021552521A1 (en) Aqueous pharmaceutical composition of an anti-il17a antibody and use thereof
JP2018532804A5 (https=)
EP4438056A3 (en) Compositions and methods of treating lupus nephritis
GB2558439A (en) Settable compositions with variable set times
MY209656A (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2023006086A (es) Métodos para prevenir, retrasar o aliviar enfermedades atópicas.
MA54511B1 (fr) Composition ophtalmique nutraceutique pour le traitement de pathologies retiniennes a composante neovasculaire
MX2020009496A (es) Metodo para tratar asma o enfermedad alergica.
EA202091811A1 (ru) Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы
MX2020006905A (es) Composiciones farmaceuticas liquidas orales de aminosalicilatos.
AR114357A1 (es) Composiciones anticonceptivas con efectos cardiovasculares reducidos
MX2024002584A (es) Tratamientos para la dermatitis atopica.
Gelbier Origins of dental education and training in the USA and UK